2 842

Cited 12 times in

Partial virological response to entecavir in treatment-naive patients with chronic hepatitis B.

 Young Eun Chon  ;  Seung Up Kim  ;  Chun Kyon Lee  ;  Jeong Heo  ;  Ja Kyung Kim  ;  Ki Tae Yoon3, Mong Cho  ;  Kwan Sik Lee  ;  Dong Hwan Kim  ;  Eun Hee Choi  ;  Jun Yong Park  ;  Do Young Kim  ;  Chae Yoon Chon  ;  Kwang-Hyub Han  ;  Sang Hoon Ahn 
 ANTIVIRAL THERAPY, Vol.16(4) : 469-477, 2011 
Journal Title
Issue Date
Adult ; Antiviral Agents/therapeutic use* ; DNA, Viral/blood* ; Female ; Guanine/analogs & derivatives* ; Guanine/therapeutic use ; Hepatitis B virus/drug effects* ; Hepatitis B virus/genetics ; Hepatitis B virus/physiology ; Hepatitis B, Chronic/drug therapy* ; Hepatitis B, Chronic/virology ; Humans ; Male ; Middle Aged ; Predictive Value of Tests ; Time Factors ; Treatment Outcome
BACKGROUND: The proposed definition of a partial virological response (PVR) to nucleos(t)ide analogue therapy in the 2009 European Association for the Study of the Liver (EASL) guidelines is based on limited evidence, especially in terms of the cutoff HBV DNA level and the time point at which to judge it. This study assessed optimal PVR criteria for predicting virological response (VR) at week 96 in treatment-naive patients with chronic hepatitis B (CHB) receiving entecavir (ETV).

METHODS: A total of 175 patients (126 men, 49 women) who completed 96 weeks of first-line ETV therapy were prospectively recruited. For predicting VR at week 96, the area under the receiver operating characteristic curve (AUC) was used to find the optimal time point and the Youden index was used to calculate the optimal cutoff HBV DNA level.

RESULTS: After 96 weeks of ETV therapy, 139 (79.4%) patients achieved VR. The AUC at week 48 was significantly better than that at week 24 for predicting VR at week 96 (P=0.023). The optimal cutoff HBV DNA level at week 48 was 35 IU/ml. Forty-one (23.4%) patients met this PVR criteria of ETV (HBV DNA level >35 IU/ml at week 48).

CONCLUSIONS: An HBV DNA level >35 IU/ml at week 48 is the optimal PVR criteria for predicting non-VR at week 96 in treatment-naive patients with CHB who are receiving ETV. This study supports the proposed EASL PVR for ETV based on scientific evidence.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Biomedical Systems Informatics (의생명시스템정보학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Do Young(김도영)
Kim, Seung Up(김승업) ORCID logo https://orcid.org/0000-0002-9658-8050
Kim, Ja Kyung(김자경) ORCID logo https://orcid.org/0000-0001-5025-6846
Park, Jun Yong(박준용) ORCID logo https://orcid.org/0000-0001-6324-2224
Ahn, Sang Hoon(안상훈) ORCID logo https://orcid.org/0000-0002-3629-4624
Lee, Kwan Sik(이관식) ORCID logo https://orcid.org/0000-0002-3672-1198
Chon, Young Eun(전영은)
Chon, Chae Yoon(전재윤)
Choi, Eun Hee(최은희)
Han, Kwang-Hyub(한광협) ORCID logo https://orcid.org/0000-0003-3960-6539
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.